On May 25, 2022 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the following presentations by Company management at upcoming investor conferences will be webcast (Press release, ImmunoGen, MAY 25, 2022, View Source [SID1234615058]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 42nd Annual Growth Stock Conference
June 8 at 11:20am CT / 12:20pm ET
Jefferies Healthcare Conference
June 9 at 9:30am ET
A webcast of each presentation will be accessible through the "Investors and Media" section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

On May 25, 2022 Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, reported that it has entered into a collaboration and supply agreement with Agenus Inc., an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, to support a clinical trial evaluating the combination of OBT076 with the anti-PD1 checkpoint inhibitor (CPI) balstilimab (Press release, Oxford BioTherapeutics, MAY 25, 2022, View Source [SID1234615056]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OBT has observed near complete responses in two chemotherapy-refractory advanced cancer patients with low to no PD-L1 expression after 2-5 cycles of OBT076 and 1-2 cycles of a CPI, indicating preliminary signs of clinical activity. Immuno-blood profiling during translational work on these patients revealed a potential novel immuno-oncology mechanism for immune system reactivation and tumor shrinkage.

OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus´ proprietary CPI, balstilimab. Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications.

"I am very excited about our new partnership with Agenus, which will allow us to progress the clinical development of OBT076 in combination with balstilimab," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. "Our preliminary data suggest that depletion of CD205+ immuno-suppressive cells and subsequent T-cell activation after OBT076 treatment followed by a single cycle of a CPI coincides with the rapid resolution of the primary tumor, as well as metastases, and we believe that balstilimab is the ideal combination agent for these studies."

Under the terms of the agreement, OBT will be the sponsor of the combination trial and responsible for operational execution, and Agenus will provide drug supply and scientific support.

"We look forward to collaborating with Oxford BioTherapeutics to bring this novel combination to patients," said Steven O’Day, MD, Chief Medical Officer of Agenus. "The clinical data generated with OBT076 in advanced solid tumors is promising, and we believe will broaden the therapeutic benefit of balstilimab observed across treatment-resistant tumors."

The study will be conducted in the US as well as in several European countries including France, Germany, Belgium and Greece, and will focus on patients with solid tumors including lung, gastric and ovarian cancer.

"Our initial Phase 1 findings suggest that OBT076 may activate the immune response against the tumor through a potentially novel mechanism in some patients; based on these encouraging results, we are advancing OBT076 into the next stage of clinical development in combination with a CPI," said Rahim Fandi, MD, PhD, Chief Medical Officer (CMO) of Oxford BioTherapeutics. "With their deep experience in the field of immune-oncology, Agenus is the ideal partner for us in this next stage of OBT076’s development."

About OBT076

OBT’s lead clinical program, OBT076, an ADC utilizing an ImmunoGen toxin, initiated expansion in a U.S. Clinical Trial in 2021 in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed. Infiltration of tumors by immunosuppressive cells correlates with adverse outcomes (lower progression free and overall survival), suggesting that this process contributes to the progression of several cancers. OBT076 is advancing into Phase 1b trials assessing the efficacy of OBT076 as a monotherapy as well as in combination with a CPI in both checkpoint-naïve and resistant patients with solid tumors. Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients. OBT is also planning for later-stage trials of OBT076, including in combination with a CPI.

On May 25, 2022 Harbour BioMed ("HBM", HKEX: 02142) reported that it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in Australia (Press release, Harbour BioMed, MAY 25, 2022, View Source [SID1234615055]). This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of HBM7008 in patients with solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HBM7008 is generated from our unique and innovative HBICE platform, leveraging the advantages of HBM HCAb and H2L2 platforms. It targets Tumor-Associated Antigen (B7H4), mediated crosslinking T cell activation through 4-1BB. B7H4 is overexpressed on a variety of solid malignancies, including breast, ovarian, endometrial, and non-small cell lung cancers. With its crosslinking dependent specificity on tumors and potent immune modulation activity, HBM7008 has shown excellent safety profile with strong anti-tumor efficacy in the pre-clinical study, including completed response observed in the mouse tumor model.

As the first-in-class bispecific antibody targeting B7H4 and 4-1BB, HBM7008 is expected to lead the development of next-generation immunotherapeutic. Following its global innovation and development strategy, Harbour BioMed will advance the global clinical development project of HBM7008 at full speed.

About HBM7008

HBM7008 is a bispecific antibody targeting Tumor Associated Antigen B7H4x4-1BB that not only displays high potency in the T cell co-stimulation and tumor growth inhibition, and potentially may also translate to better safety due to its strict dependency on TAA-mediated crosslinking T cell activation. HBM7008 is one of the fully human bispecific antibodies developed from the HBICE platform of the Company. It is the only bispecific antibody against these two targets globally. Its unique specificity on tumors and immune modulation activity makes it a promising therapeutic in PD-L1 negative or PD-1/PD-L1 resistant patients. It also has the potential to avoid 4-1BB liver toxicity risk observed in other products with the benefit of its innovative biology mechanisms and bispecific design.

On May 25, 2022 Convergent Therapeutics Inc., a clinical stage radiopharmaceutical company, and IONETIX Corporation, a leading cyclotron technology, and isotope manufacturing company, reported a long-term supply agreement for the therapeutic medical radioisotope, actinium-225 (Ac-225) (Press release, Convergent Therapeutics, MAY 25, 2022, View Source [SID1234615054]). The agreement will support Convergent’s pipeline of next-generation radiotherapies including its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225. CONV01-α is currently being investigated as a potentially groundbreaking treatment for prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ac-225 is a high-energy alpha-emitting radioisotope of great interest for the treatment of cancer as it carries sufficient radiation to cause cancer cell death while limiting unwanted off-target radiation. Convergent is investigating its use in targeted radiopharmaceutical therapies, which combine select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients. Clinical research and commercial use of Ac-225 are constrained by its short supply, due to limitations of current production technology, emphasizing the need for strategic supply agreements.

"IONETIX is dedicated to establishing a secure and reliable supply of Ac-225," said David Eve, Vice President of Medical Affairs for IONETIX. "We have installed our first cyclotron in Lansing, Michigan that will be fully commissioned to produce Ac-225 later this year. We look forward to supporting Convergent in advancing the development of CONV01-α and other new innovative radiopharmaceuticals."

"Radiopharmaceuticals like CONV01-α represent an exciting new approach for the treatment of cancer, and the recent approval of Pluvicto demonstrates the growing need for targeted radiotherapies," said Philip Kantoff, M.D., Chief Executive Officer of Convergent Therapeutics. "CONV01-α is a monoclonal antibody radiolabeled with Ac-225 and specifically designed to bind to PSMA, which is highly expressed in prostate cancer, to deliver therapeutic doses of radiation directly into prostate cancer cells."

"Convergent is committed to building a robust pipeline of best-in-class radiopharmaceutical therapies for patients in need; the first step of which is the continued clinical development of CONV01-α. IONETIX has dedicated its manufacturing activities to support the advancement of innovative radiopharmaceuticals such as CONV01-α," said Alexander Brown, Chief Operating Officer of Convergent Therapeutics.

On May 25, 2022 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, reported that Ryan Spencer, Chief Executive Officer and Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat during the William Blair 42nd Annual Growth Stock Conference in Chicago, Illinois on Monday June 6, 2022 at 4:40 p.m. C.T (Press release, Dynavax Technologies, MAY 25, 2022, View Source [SID1234615053]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source and a replay will be available following the event.